福元医药(601089) - 北京福元医药股份有限公司投资者关系活动记录表（3）

Group 1: Impact of National Volume Procurement - The company has won bids for 11 products under the national volume procurement policy since its implementation [1] - In the first half of 2024, the company achieved a revenue of 1.655 billion RMB, an increase of 1.58% compared to the same period last year [1] Group 2: R&D Investment - The company focuses its R&D on clinical needs for major diseases and chronic illnesses, employing a strategy that combines innovative and generic development [2] - In the first half of 2024, R&D expenses amounted to 189 million RMB, reflecting a year-on-year growth of 38.19% [2] Group 3: Sales Expense Rate - The company's sales expense rate will be determined based on the bidding and sales performance of individual products [2]